Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients With Combined Pulmonary Fibrosis and Emphysema: Data From the INBUILD Trial

被引：0
|
作者：
Cottin, V. [1 ]
Flaherty, K. R. [2 ]
Inoue, Y. [3 ]
Valenzuela, C. [4 ]
Mueller, H. [5 ]
Rohr, K. B. [6 ]
Wells, A. U. [7 ,8 ]
机构：
[1] Claude Bernard Univ Lyon 1, Louis Pradel Hosp, Hosp Civils Lyon, Natl Reference Ctr Rare Pulm Dis,UMR 754, Lyon, France
[2] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[3] Natl Hosp Org, Clin Res Ctr, Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[4] Univ Autonoma Madrid, Hosp Univ Princesa, Madrid, Spain
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[7] Imperial Coll, Natl Inst Hlth Res, Resp Biomed Res Unit, Royal Brompton & Harefield NHS Fdn Trust, London, England
[8] Imperial Coll, Natl Heart & Lung Inst, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2578
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effect Of Nintedanib On Decline In Forced Vital Capacity (FVC) Over Time In The Inpulsis® Trials In Patients With Idiopathic Pulmonary Fibrosis
    Maher, T. M.
    Flaherty, K. R.
    Azuma, A.
    Cottin, V.
    Stansen, W.
    Quaresma, M.
    Wells, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [2] Effect of Nintedanib on FVC Decline in Patients with Progressive Fibrosing ILDs: Data from the INBUILD Trial
    Cottin, V.
    Inoue, Y.
    Kolb, M.
    Rosas, I.
    Tomassetti, S.
    Quaresma, M.
    Goeldner, R.
    Schlenker-Herceg, R.
    Brown, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [3] Improvement In Forced Vital Capacity (FVC) With Nintedanib In Patients With Idiopathic Pulmonary Fibrosis (ipf): Results From The Inpulsis Trials
    Flaherty, K. R.
    Kolb, M.
    Vancheri, C.
    Tang, W.
    Conoscenti, C. S.
    Richeldi, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [4] Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial
    Matteson, Eric L.
    Aringer, Martin
    Burmester, Gerd R.
    Mueller, Heiko
    Moros, Lizette
    Kolb, Martin
    CLINICAL RHEUMATOLOGY, 2023, 42 (09) : 2311 - 2319
  • [5] Forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) - modelling the myth
    Wijsenbeek, Marlies
    Santermans, Eva
    Ford, Paul
    Kreuter, Michael
    Verbruggen, Nadia
    Meyvisch, Paul
    Wuyts, Wim
    Brown, Kevin
    Lederer, David
    Maher, Toby
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [6] Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial
    Eric L. Matteson
    Martin Aringer
    Gerd R. Burmester
    Heiko Mueller
    Lizette Moros
    Martin Kolb
    Clinical Rheumatology, 2023, 42 : 2311 - 2319
  • [7] Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis
    Lasseniusa, Mariann I.
    Toppila, Iiro
    Pontynen, Nora
    Kasslin, Laura
    Kaunisto, Jaana
    Kilpelainen, Maritta
    Laitinen, Tarja
    EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2020, 7 (01):
  • [8] Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis
    Flaherty, Kevin R.
    Kolb, Martin
    Vancheri, Carlo
    Tang, Wenbo
    Conoscenti, Craig S.
    Richeldi, Luca
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (02)
  • [9] Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome
    Cottin, Vincent
    Hansell, David M.
    Sverzellati, Nicola
    Weycker, Derek
    Antoniou, Katerina M.
    Atwood, Mark
    Oster, Gerry
    Weber, Frank
    Kirchgaessler, Klaus-Uwe
    Collard, Harold R.
    Wells, Athol U.
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [10] Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) by GAP Stage
    Ryerson, C. J.
    Chaudhuri, N.
    Perez, E. R. Fernandez
    Kim, Y.
    Silva, R. S.
    Wuyts, W. A.
    Mueller, H.
    Rohr, K. B.
    Kolb, M. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
12345